LGP Cannatrek generated A$4.4 million in net operating cash flow on unaudited quarterly revenue of A$26.0 million, providing the first clean look at the merged group’s operations. Cost synergies, Danish production upgrades and UK expansion are advancing, while a pending TGA penalty remains an unresolved risk.
- A$26.0 million unaudited quarterly revenue and A$4.4 million operating cash flow
- A$22.3 million cash balance and A$5.2 million borrowings excluding leases
- A$3.0 million annual merger synergy program actioned
- Danish facility upgrades target higher yields and lower production costs
- UK clinic, wholesale and in-country expansion plans progressing
First full-quarter test delivers positive operating cash flow
The newly combined LGP Cannatrek Group has cleared its first full-quarter operating test with A$26.0 million in unaudited revenue and A$4.4 million in net cash from operating activities. The figures offer the first like-for-like quarterly view since Little Green Pharma (ASX:LGP) completed its merger with Cannatrek on 1 June.
The reporting period is materially cleaner than the previous quarter, which combined Cannatrek’s full April-to-June cash flows with only LGP’s post-merger activity from 1 June. The company says customer receipts reached A$26.8 million in the September quarter, against A$15.0 million of product manufacturing and operating costs, A$4.3 million in staff costs and A$3.4 million in administration and corporate expenses.
Merger integration reaches the savings phase
The result arrives as the group moves from transaction execution to integration. LGP said initiatives targeting A$3.0 million in annual post-merger cost synergies had been actioned, including the consolidation of Australian inventory at Shepparton, supplier onboarding and the combination of customer support functions.
The merger itself had been completed after the Cannatrek merger approval, which created the combined medicinal cannabis group. LGP Australia went live on the group’s Business Central enterprise resource platform on 1 October, after quarter-end, while the Dynamics 365 customer relationship system is still being implemented and a single-tenant Microsoft 365 migration is expected to finish in November.
Danish investment targets yield and production costs
The company is also putting capital into its Danish production base. Under-canopy lighting is being rolled out across all flower rooms after what LGP described as better-than-expected trial results, while post-harvest equipment upgrades are intended to improve yields and reduce cost per gram.
The Danish research pipeline has completed initial growing trials for 12 new strains, with six moving to the next stage and another 12 entering initial trials. LGP said Denmark-grown flower is also being assessed as a replacement for existing Cannatrek product lines, potentially increasing the use of internal supply across the group.
European expansion broadens beyond Germany
Australia remained the group’s principal market, accounting for 82% of sales, while Europe contributed 18% through LGP Denmark. Flower represented 81% of group sales; edibles and vapes increased their weighting during the quarter, while oils softened on weaker LGP oil sales. Cornerfield sales rose 14% from the prior quarter, although the group’s sales mix remained weighted roughly 65% to Cannatrek brands and 35% to LGP.
Germany continues to provide the clearest market-volume signal, with medicinal cannabis flower imports reaching a revised 67.6 tonnes in the first quarter of 2026, 12.1% above the previous quarter. LGP said the removal of flower from Germany’s statutory health insurance reimbursement system in July appeared not to have materially affected the self-pay market, while proposed restrictions on mail-order dispensing remain under parliamentary consideration.
In the United Kingdom, a three-year expansion plan is being put into action. A London office has opened, Karen Bowell has started as UK Country Manager and the group is progressing a partnership with an established clinic operator, with operations expected to begin in the second half of FY27. France remains dependent on a pending implementing decree, while LGP expects to submit its French applications before the end of 2026; a shipment to Italy was delivered after quarter-end.
Cash position strengthened but regulatory liability remains
LGP finished September with A$22.3 million in cash and A$5.2 million of borrowings excluding leases. The Appendix 4C also identified A$9.2 million in unused financing facilities. Operating cash generation was partly offset by A$3.0 million of investing outflows, including A$0.6 million spent on property, plant and equipment, while financing activities contributed A$0.5 million.
The major unresolved financial variable is the TGA regulatory investigation. LGP said it expects the eventual penalty to be material, but anticipates it will remain within the limits of the CV Shares conversion mechanism. The filing does not disclose the amount or timing, leaving the eventual impact on the group’s capital structure and cash resources open.
Separately, the post-quarter-end sale of Health House International to Medicann Health Australia is intended to reduce duplication with Cannatrek’s Greenship distribution platform and lower the group’s cost base. The immediate question is whether the first full-quarter cash result can be sustained while LGP funds Danish upgrades, builds its UK presence and absorbs the still-uncertain TGA cost.
Bottom Line?
The first full-quarter numbers show positive operating cash generation, but the next test is converting merger synergies and European expansion into repeatable cash flow without allowing the TGA penalty or production investment to erode liquidity.
Questions in the middle?
- Can the A$4.4 million quarterly operating cash flow be sustained once integration costs and expansion spending normalise?
- What will the TGA penalty amount to, and how will the CV Shares conversion mechanism affect existing shareholders?
- Will Danish yield improvements and the UK clinic partnership generate enough incremental scale to justify the group’s expansion program?